Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic ...
Genomic sequencing has come a long way in a short time, and its potential to drive even faster innovations in precision medicine is enormous. To capitalize on that opportunity, however, health systems ...
Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, ...
Patients with classic NF1 including the presence of cutaneous neurofibromas or Lisch nodules, as no genetic heterogeneity demonstrated so far associated with this phenotype. The NF1-only by NGS ...
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...
Ultima Genomics, Inc., a developer of ultra-high-throughput sequencing systems, continues its mission to enable sequencing at scale with the unveiling of the UG200 Series and next generation Solaris 2 ...
Patients with multiple CALMs w/wo skinfold freckling and no other typical NF1 associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas). The DNA-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results